Plaquenil is used to treat or prevent malaria, a disease caused by parasites that enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia. Plaquenil eye grib waves Sam's club pharmacy hydrochloride hydroxychloroquine Today, Plaquenil and other antimalarials are also used to treat and help prevent symptoms caused by certain autoimmune diseases such as rheumatoid arthritis RA, systemic lupus erythematosus, and discoid lupus, even though these diseases are not caused by malaria parasites. Plaquenil belongs in a class of medications known as disease-modifying. Plaquenil ® hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-4-7-Chloro-4-quinolylaminopentylethylamino ethanol sulfate 11. Its structural formula is WebMD discusses the symptoms, causes, and treatment of neutropenia, an immune system condition that may lead to infections. Plaquenil is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. This medicine is not effective against all strains of malaria. Plaquenil autoimmune neutropenia Plaquenil Uses, Dosage & Side Effects -, Plaquenil - FDA prescribing information, side effects and uses Hydroxychloroquine pn singlecare Any one have any experience or info regarding pre-existing precancerous conditions and the effects of Plaquenil on the immune system. I see so much info on the net where some says that Plaquenil has very mild effect on immune system except for eye issues --- Other info says it is an immunosuppressant. Plaquenil and its affect on the immune system DailyStrength. Neutropenia Causes, Symptoms, and Treatment. HYDROXYCHLOROQUINE - ORAL Plaquenil side effects.. Autoimmune neutropenia What every physician needs to know about autoimmune neutropenia Autoimmune neutropenia AIN is a heterogeneous disorder that is characterized by a decreased neutrophil. The observation of neutropenia and enhanced neutrophil-induced tissue damage in patients with SLE is difficult to reconcile. One possibility is that a proportion of the neutrophils that infiltrate organs are actively undergoing NETosis or apoptosis, which could contribute to promotion of neutropenia but also to organ damage and immune. This article is a review of different management strategies for the hematological manifestations of systemic lupus erythematosus SLE, the strategies include immunosuppressive drugs, some noval therapies and B-cell depletion for refractory thrombocytopenia in patients with SLE and in antiphospholipid antibody syndrome associated with SLE.